Omnicell, Inc. (OMCL - Free Report) is progressing well with its three-legged strategy that covers market expansion through delivery of differentiated, innovative solutions; expansion into new markets, primarily outside the United States; as well as expansion through strategic partnerships and acquisition of new technologies.
In the past year, the company’s shares have outperformed the industry. The stock has rallied 62.7%, against the industry’s 3.2% rise and the S&P 500’s 1% fall.
This leading developer and marketer of end-to-end automation solutions for the medication-use process has a market cap of $3.28 billion. The company has an expected earnings growth rate of 15% for the next three to five years.
Riding on solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
Product Innovation Driving Growth: Recently, the company is witnessing strong adoption of its G4 platform. It is upbeat about the launch of the XR2 Central Pharmacy Robot and the IVX Workflow.
Autonomous Pharmacy Model Holds Potential : Omnicell believes that automation tools like the XR2 Central Pharmacy Robot and the IV technology will lower medication dispensing and compounding costs. One notable example of customer integrating the Autonomous Pharmacy solution is Inova Health Care — Northern Virginia's leading nonprofit healthcare provider — that serves more than 2 million individuals annually.
Focus on Geographic Expansion: The company is focusing on its strategy of expanding into new markets. The initiative is driving significant growth in the Non-Acute Care segment. While the company continues to focus on the Middle East and South Africa, it sees greater adoption of technologies in Australia, the U. K., parts of Asia, Germany and France.
Strategic Acquisitions and Partnerships Add Value: The company's most recent buyout is InPharmics, a Mississippi-based technology and services company. This is likely to enable Omnicell to expand the capabilities of its Performance Center. In the first quarter, Omnicell inked several strategic deals with healthcare providers based on its XT platform.
Which Way are Estimates Heading?
For the second quarter of 2019, the Zacks Consensus Estimate for earnings is pegged at 64 cents, which indicates 39.13% growth from the year-ago quarter’s figure. The same for revenues is pegged at $213.2 million, calling for year-over-year growth of 12.9% from the prior-year quarter’s number.
For 2019, the Zacks Consensus Estimate for earnings is pegged at $2.77, suggesting 32.54% year-over-year growth from the year-ago quarter’s figure. The same for revenues is pegged at $891.9 million, suggesting 13.3% rise from the prior-year number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Cerner Corporation (CERN - Free Report) , Penumbra (PEN - Free Report) and Bruker Corporation (BRKR - Free Report) . While Cerner sports a Zacks Rank #1 (Strong Buy), Penumbra and Bruker carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 11.7%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>